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Introduction
The antipsychotic action of typical neuroleptics (i.e. reduction of
positive symptoms such as hallucinations, and psychotic and
paranoid perception of subjective reality) is associated with the
ability of these drugs to block the striatal dopamine (D2) receptor.
Under treatment with typical neuroleptics, at least 5–30% of
patients develop severe side-effects, namely extrapyramidal
symptoms (EPS), which contribute to noncompliance rates
approaching 50% (Kane, 1987; Tollefson and Sanger, 1997).
Clozapine was the first atypical neuroleptic and preceded the
introduction of a group of neuroleptics characterized not only by
dopamine D2 receptor, but also 5-HT2A receptor antagonism. A
ten-fold higher affinity for 5-HT2A receptors than for D2 receptors
has been proposed as the key property of the ‘atypicals’ (Meltzer et
al., 1989). Substances fulfilling this criterion demonstrated a very
low tendency to induce EPS and tardive dyskinesia (Kapur et al.,
1997, Kapur, 1998; Kapur et al., 1998).
Further atypical neuroleptics introduced over the last few years
(e.g. risperidone, olanzapine, sertindole, ziprasidone and quetipine)
are still under experimental and clinical investigation and their
receptor profiles have been established in vitro and in vivo
(Gerlach and Peacock, 1995; Bymaster et al., 1996; Richelson,
1996; Schotte et al., 1996).
Beside clozapine, risperidone and olanzapine are the most
frequently clinically used substances of this group. For risperidone
and its active metabolite 9-OH-risperidone, an eight- and 17-fold
lower affinity for the D2 receptor, respectively, with slightly less
affinity for D3 compared to haloperidol, was shown in vivo in rats
(Schotte et al., 1996). Both compounds exhibited the highest
affinity for the 5-HT2A receptor and the least affinity for the D2
receptor (potency ratios 19 and 22, respectively). Olanzapine (2-
methyl-4-(4-methyl)-1-piperazinyl)-1OH-thieno[2,3-b]
[1,5]benzodiazepine) reveals a pharmacological profile similar to
that of clozapine. Nevertheless, preclinical studies have
demonstrated that the D2 receptor affinity of olanzapine is higher
than that of clozapine (Bymaster et al., 1996). Comparison studies
between risperidone and olanzapine in rats have revealed lower
affinity constants (Ki) of risperidone for the dopaminergic D1 and
histaminergic (H1) receptors, and of olanzapine for the
dopaminergic D2 and D3, serotonergic receptors, apart from 5-
HT2C and adrenergic α1 and α2 receptors (Bymaster et al., 1996;
Schotte et al., 1996). In Table 1, the Ki values of both substances,
compared to haloperidol, are listed according to the data of Schotte
et al., 1996.
Clinical trials have defined efficacy and optimum doses for both
risperidone and olanzapine (Marder and Meibach, 1995; Peuskens,
1995; Beasley et al., 1996). Risperidone has been found to be
superior to haloperidol with respect to efficacy and safety
(Peuskens, 1995); until recently, the recommended daily dose for
risperidone was up to 8 mg (Peuskens, 1995; Möller et al., 1997)
while clinical dose recommendations for olanzapine treatment are
up to 20 mg/day (Tollefson et al., 1997; Tran et al., 1997b).
The mode of action of both substances in humans is still under
investigation. It should be noted that the results of receptor
occupancy from in-vitro or in-vivo animal experiments cannot be
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assumed to indicate the binding of a drug in humans (Arndt et al.,
1997). For example, a difference between the striatal dopamine D2
receptor occupancy rate in animals and humans was demonstrated
for the neuroleptic remoxipride (Busatto et al., 1995). Therefore,
there is a need to study the receptor profile of new antipsychotic
substances in vivo in humans. Nuclear medicine imaging
techniques such as 123I-iodobenzamide (IBZM)-SPECT and 11C-
raclopride- or 14N-methylspiperone-PET are potentially suitable
methods for this purpose.
For risperidone, SPECT and PET data on the degree of
dopamine D2 receptor occupancy in humans are available. Data
show that risperidone given in different dose regimes occupies the
striatal dopamine D2 receptor at a level close to that of haloperidol
(Kerwin et al., 1993; Busatto et al., 1995; Farde et al., 1995;
Küfferle et al., 1996).
In a number of PET and SPECT studies, there are conflicting
findings regarding the striatal D2 receptor occupancy with
olanzapine. Higher D2 occupancy has been demonstrated with
SPECT (Kasper et al., 1998; Tauscher et al., 1999; Meisenzahl et
al., 2000) and PET (Nyberg et al., 1997; Kapur et al., 1998b), but a
lower D2 occupancy rate, similar to that of clozapine, has been
reported with SPECT (Pilowsky et al., 1996). Interestingly, a
recent prospective double-blind SPECT study with 10 mg
olanzapine reported a mean striatal D2 occupancy of 49%
(Bernardo et al., 2001). Kapur analysed D2 receptor occupancy
with PET and compared treatment groups in multiple-dose, steady-
state regimens. By fitting, it was demonstrated that risperidone
given in a daily dose of 5 mg has a binding level equal to that of
olanzapine 20 mg/day (Kapur et al., 1999).
The aim of the present SPECT investigation was to compare the
amount of striatal dopamine D2 receptor blockade of risperidone
and olanzapine in schizophrenic patients. Different doses of the
drugs were used; the dose range was chosen according to the
clinical needs but was within the clinically recommended range.
This means that no prospectively fixed doses were given, but none
of the patients was treated with higher or lower doses than defined
in phase three clinical trials (Peuskens, 1995; Möller et al., 1997;
Tollefson et al., 1997; Tran et al., 1997b.
Methods
Subjects
Consecutively admitted inpatients with a diagnosis of
schizophrenia or a schizoaffective illness according to DSM-
IV/ICD-10 criteria were included in the study. Eight males and 12
females were treated with risperidone and eight males and five
females with olanzapine. The mean (± SD) age was
39.2 (± 13.26) years (range 19–68 years) for the risperidone and
35.0 (± 12.8) years (range 22–63 years) for the olanzapine group.
Groups were comparable with respect to age (unpaired t-test,
t = 0.906, p = 0.372) and gender (unpaired t-test, t = –1.199,
p = 0.239).
According to DSM IV/ICD-10 criteria, 13 patients were
diagnosed as paranoid, three as disorganized and four as
schizoaffectively ill in the risperidone group, while there were six
paranoid, five disorganized and two schizoaffective patients in the
olanzapine group.
For patients pretreated with oral neuroleptics (12 patients in the
risperidone and 10 patients in the olanzapine group), a 3-day
washout period preceded commencement of the study medication.
The dependency of receptor blockade on the dose per mg/kg body
weight was analysed. Before the SPECT scan was performed,
patients had been treated for 1–33 (mean ± SD,  8.8 ± 7.59) weeks
with risperidone at a daily dose of 2–8 mg per day (mean
4.85 ± 2.28 mg); mg/kg body weight 0.03–0.13 (mean ± SD,
0.07 ± 0.03). Olanzapine was administered at a daily dose of
5–20 mg per day (mean ± SD,  11.9 ± 12.8); mg/kg body weight
0.05–0.28 (mean ± SD, 0.16 ± 0.07) for a minimum of 2 to a
maximum of 8 (mean ± SD, 3.7 ± 1.6) weeks (Table 2). None of
the patients were receiving any other neuroleptic substance at the
time of the SPECT. Patients having been treated with depot
formulation 3 months before the study entrance were excluded.
Concomitant medication was restricted to biperiden in both groups.
However, in the risperidone group, one patient received doxepine,
another amitryptiline, and one occasionally benzodiazepines.
Ethical approval for the SPECT investigation was provided by
the local ethics committee and the study was performed in
accordance with the ethical standards defined in the Declaration of
Helsinki 1975, revised Hong Kong 1989. All patients gave their
informed consent to participate in the study.
SPECT investigation
In both treatment groups, 123I-IBZM-SPECT was performed using
identical protocols. SPECT scanning was typically performed 14 h
after the last dose of antipsychotic medication (i.e. the last
medication was given on ward at the evening before the day of
scintigraphy). 123I-IBZM was chosen as a highly selective
radiotracer for striatal D2 receptors. All patients were administered
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Table 1 Ki values of risperidone, olanzapine and haloperidol from in-vitro binding studies in animal brain (Schotte, 1996)
Receptor Species Risperidone Olanzapine Haloperidol
D1 Rat 620 250 270
D2 Rat 3.3 17 1.4
D3 Cloned rat 13 54 21
5-HT1A Rat 250 – 3080
5-HT1B Rat 2720 2850 > 5000
5-HT2A Rat 0.16 1.9 25
5-HT2C Pig 63 7.1 > 5000
5-HT3 Mouse > 5000 84 > 5000
5-HT6 Cloned rat 420 2.5 > 5000
5-HT7 Cloned mouse 1.6 120 380
α1 Rat 2.3 60 19
α2 Rat 7.5 – > 5000
H1 Guinea-pig 2.6 3.5 730
 at LMU Muenchen on May 16, 2013jop.sagepub.comDownloaded from 
185 MBq (5 mCi) of 123I-IBZM intravenously as a bolus injection.
SPECT scans were acquired using a triple-headed gamma camera
equipped with high resolution fan-beam collimators (Prism 3000
XP, Picker Intl., Cleveland, OH, USA). The acquisition parameters
included a 20% energy window centred on 159 keV, a rotational
radius of 13 cm or less, 120 projection angles over 360° and a
128 × 128 matrix with a pixel width of 2.11 mm in the projection
domain. Data collection started 120 min after injection and lasted
for approximately 30 min (45 s per projection). Reconstruction of
projection images was performed by filtered back-projection
followed by filtering with a low pass filter. Chang’s first order
method was used for uniform attenuation correction. Uniform
image reslicing was performed by drawing a line connecting the
anterior-most aspect of the frontal pole to the posterior-most aspect
of the occipital pole. This procedure approximates the line
connecting the anterior and posterior commisures (AC–PC line).
To assess specific tracer uptake in the striatum, the region of
interest (ROI) technique was used. Mean specific activity in basal
ganglia regions was calculated by subtracting the mean counts per
pixel in the background (BKG) from the mean counts per pixel in
the basal ganglia region, and dividing the result by the mean counts
per pixel in the background [(STR – BKG)/BKG]. Templates were
used to define striatal ROIs. The size and shape of the templates
was established and optimized using the data from a control group,
as previously described (Dresel et al., 1998). The predefined
templates were adjusted to fit individuals so that only minor
corrections according to the individual shape and size were
necessary. By performing this procedure, intraobserver reliability
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Table 2 Characteristics of the risperidone group
Risperidone DSM IV/ICD-10 Dose (mg/kg Total dose Duration of
treated patients Gender (M/F) Age (years) diagnosis body weight) per day (mg) treatment (weeks)
1 F 56 16 schizophrenic 0.029 2 1
2 M 29 4 schizoaffective 0.029 2 3
3 M 32 0.037 3 3
4 F 63 0.039 2 10
5 M 42 0.041 3 9
6 F 38 0.041 3 6
7 F 33 0.041 3 33
8 F 25 0.042 3 12
9 F 62 0.053 4 8
10 M 47 0.058 4 1
11 M 36 0.059 4 15
12 M 20 0.067 6 6
13 M 35 0.075 6 8
14 F 24 0.093 8 8
15 F 47 0.100 8 22
16 F 36 0.100 6 6
17 F 24 0.100 8 9
18 F 56 0.100 8 1
19 M 35 0.120 8 6
20 F 38 0.128 6 8
Mean ± SD 39.15 ± 13.24 0.068 ± 0.32 4.85 ± 2.28 8.75 ± 7.59
Risperidone D2-occupancy
treated patients [STR – BKG]/BKG rate (%) Comedication
1 0.60 32
2 0.62 37
3 0.60 37 Benzodiazepines
(occasionally)
4 0.30 69
5 0.60 37
6 0.40 43
7 0.39 59 Amitryptiline
8 0.40 59
9 0.40 59
10 0.39 57
11 0.40 59
12 0.50 44 Doxepine
13 0.40 58
14 0.20 79
15 0.30 69
16 0.07 78
17 0.27 91
18 0.20 72 (All patients:
19 0.20 78 biperiden if
20 0.32 65 necessary)
Mean ± SD 0.38 ± 0.15 59.1 ± 16.6
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was enhanced. The operator was blind to clinical data. D2 receptor
occupancy of the healthy controls registered by 123I-IBZM-SPECT
was considered to be normal. No morphological fusion with
magnetic resonance imaging images was used. The non-specific
background activity was estimated by drawing a ROI around the
frontal cortex. In each patient, data were evaluated in the two
consecutive transverse slices showing the highest tracer
accumulation in the basal ganglia. Results are given as arithmetic
mean of the activity of the two slices.
123I-IBZM binding in the patients was compared to an age-
matched control group and to patients treated with olanzapine.
Patient data were expressed as a percentage of normal binding with
a 100% value of [(STR – BKG)/BKG] = 0.95 for both the
risperidone and the olanzapine group.
Measurements in controls were used to assure that this approach
resulted in comparable data. The control group consisted of 10
healthy, age- and sex-matched subjects. There was no significant
difference between patients and healthy controls with respect to
age and gender.
Statistical analysis
For statistical analysis of SPECT, clinical and risperidone group
data, a one-way analysis of variance (ANOVA) was performed
with post-hoc tests (Scheffé) to test the significance of differences.
Student’s t-test was performed to compare two independent groups
(i.e. risperidone versus the control group, risperidone versus the
olanzapine treatment group, low versus high risperidone group).
Mono-exponential fitting was applied to all data. Equality of
variances were tested using Levine’s test of equality of variances.
Continuous values were correlated where necessary using Pearson
correlation coefficients or Spearman’s rho. p < 0.05 was considered
statistically significant.
Results
Patients treated with risperidone showed a markedly reduced
dopamine D2 receptor binding of IBZM compared to healthy
controls, as did olanzapine-treated patients (Fig. 1). Striatal IBZM
binding in the risperidone-treated patients, expressed as [(STR-
BKG)]/BKG, was in the range 0.07–0.62 (mean 0.38 ± 0.15),
which is significantly lower than in the control group (mean
0.95 ± 0.10), as shown by statistical analysis (ANOVA: F = 115.53,
p = 0.0001). The striatal D2 receptor occupancy rate induced by
risperidone treatment was 59.1 ± 16.6%, ranging individually
between 32% and 91%. The degree of the occupancy of the
dopamine D2 receptors presented an exponential dose–response
relationship (Pearson r = –0.86, p = 0.0001) (Fig. 2). Patients’ daily
dose, duration of treatment, IBZM-binding behaviour and D2
occupancy rate are shown in Table 2.
Comedication did not seem to play an important role in our
patient group. One patient was treated with amitryptiline, another
with doxepine and a third occasionally with diazepam. Diazepam
had last been administered 1 week before the SPECT scan was
performed. D2 receptor occupancy rate of the amitryptiline-treated
patient was the same as in three patients who were not comedicated
and who received comparable or even higher doses of risperidone.
The doxepine-treated patient also had an IBZM-binding in the
range of variance, as did the patient who occasionally took
benzodiazepines (Table 2).
Comparison of the risperidone-treated with the olanzapine-
treated group revealed no significant differences with respect to the
striatal D2 receptor binding of IBZM (unpaired t-test, t = –0.066,
p = 0.947) or D2 receptor occupancy rate (unpaired t-test,
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Figure 1 IBZM-binding of risperidone and olanzapine treated patients
compared to healthy controls
Figure 2 dose-response relationship of IBZM-binding and daily dosage in
mg/kg body weight of risperidone (n = 20)
Figure 3 dose-response relationship of IBZM-binding and daily dosage in
mg/kg body weight of olanzapine (n = 13)
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t = –0.112, p = 0.911) induced by the two substances. The only
significant difference found concerned the duration of treatment:
the risperidone-treated patients had a significant longer treatment
duration with the substance (mean 8.8 versus 3.7 weeks; unpaired
t-test, t = –4.608, p = 0.0001).
The effect of duration of medication with respect to striatal
binding of IBZM was therefore tested seperately in the risperidone
and olanzapine groups. There was no correlation between duration
of medication and striatal binding of IBZM for either risperidone
(Spearmans’ rho = –0.144) or olanzapine (Spearmans’ rho =
0.475).
Discussion
The aim of our study, using SPECT, was to assess in vivo the
degree of striatal dopamine D2 receptor occupancy of risperidone
in schizophrenic patients compared to that of olanzapine. The
risperidone group included 20 patients, which to our knowledge is
the largest sample investigated to date.
Our investigation revealed that risperidone treatment led to a
significant, dose-dependent dopamine D2 receptor occupancy rate.
The hypothesis of a strong correlation between dose in mg/kg body
weight with striatal D2 receptor blocking, as hypothesized
(Tauscher et al., 1999) and confirmed (Meisenzahl et al., 2000) for
olanzapine, was therefore also confirmed for risperidone.
Testing the D2 occupancy rate of different neuroleptics in one
laboratory minimizes methodological influences. We compared our
risperidone data with the binding characteristics of a group of
olanzapine-treated patients who were highly comparable with
respect to sociodemographical characteristics. Olanzapine binding
to the striatal dopaminergic D2 receptors was proposed to be
similar to that of clozapine (Pilowsky et al., 1996). Tauscher
reported a higher blocking ability by olanzapine compared to
clozapine (Tauscher et al., 1999). In a recently published study on
olanzapine administered at higher doses than 20 mg per day,
receptor occupancy rate was still more pronounced (Meisenzahl et
al., 2000). Our data suggest that, in age- and sex-matched patients,
there is no difference in the dopamine D2 receptor blockade by
risperidone and olanzapine when these are given in the clinically
recommended dose range. Both substances show D2-binding
curves different to clozapine and more closely related to
haloperidol, although without the same steep decline.
In line with our findings, Lavalaye et al. (1999) found no
differences in the mean binding rates between both groups when
investigating the D2 occupancy by 123I-IBZM-SPECT in 13
patients treated with risperidone (daily dose mean 4.2 mg, range
2–8 mg) and 23 patients treated with olanzapine (daily dose mean
15.4 mg, range 5–30 mg) (Lavalaye et al., 1999). However, by
subdividing patients into subgroups of the most prescribed doses,
with eight patients receiving 4 mg risperidone per day, and nine
patients 15 mg olanzapine, a significantly lower occupancy rate for
the olanzapine group was detected.
Lavalaye et al. reported a mean occupancy rate of 76% in the
13 patients receiving 2–8 mg risperidone (mean dose 4.2 mg/day).
Our group, consisting of 20 patients with a 0.5 mg higher mean
dose (4.9 mg/day), shows a lower occupancy rate (59.1%). Some
methodological limitations might hinder a direct comparison.
Lavalaye et al.  performed SPECT imaging after at least 6 weeks of
steady-state treatment of atypical medication with risperidone,
whereas duration of treatment in our risperidone-treated patient
group included a time period of 1–33 weeks. Additionally,
Lavalaye et al. used different SPECT data processing, including a
different background region (occipital lobe versus the frontal lobe
in our study). Nevertheless, while the degree of occupancy of the
dopamine D2 receptors in our group presented an exponential
dose–response relationship, Lavalaye et al. were unable to detect a
relationship between the dose of risperidone and D2 receptor
occupancy.
In a SPECT investigation of 11 patients under treatment with
risperidone, Küfferle et al. (1996) reported rates of 63.8% D2
occupancy in a predefined low dose patient group (3 mg each, five
patients) versus 74.3% D2 occupancy in the high dose group (8 mg
each, six patients) (Küfferle et al., 1996). To enable direct
comparison with this study, we defined a low dose group with 11
patients receiving up to 4 mg risperidone (mean 3.1 mg/day) and a
high dose group with nine patients receiving a daily dose of
between 6 and 8 mg (mean 7.1 mg/day). These subgroups revealed
significantly different D2 occupancy rates (49.8% and 71.2%,
respectively). Therefore, especially the D2 occupancy in our high
dose range may support the findings of Küfferle et al.
A case report in a patient treated with 12 mg risperidone a day
presented a D2-SPECT-binding comparable to typical neuroleptics
(Kerwin et al., 1993). The group repeated their findings in six
patients who were being treated with risperidone at a dose of
4–12 mg daily (Busatto et al., 1995). It should be noted that the
dose range used equals the one formerly recommended for
risperidone. The data of Busatto et al. (1995) are difficult to
compare with ours in detail because they are given as binding rates
in the left versus right striatum separately. Percent binding values
of risperidone are not listed.
To date, all SPECT studies that have investigated D2 occupancy
of risperidone examined subgroups of dose ranges or were unable
to provide an exponential dose–response relationship between dose
of risperidone and D2 receptor occupancy.
Kapur et al. (1999) presented a 11C-raclopride-PET study
comparing D2- (and 5-HT2A-) receptor blockade under multiple-
dose, steady-state regimens with risperidone (n = 16, mean dose
5.01 mg/day), olanzapine (n = 17, mean dose 18.8 mg/day) and
clozapine (n = 11, mean dose 425.0 mg/day). Again in line with our
findings, they show that, in a comparable number of patients, there
is no difference in the D2-binding of 11C-raclopride in the
risperidone versus olanzapine group. Kapur fitted the 5 mg dose of
risperidone to the 20 mg dose of olanzapine as equipotent in D2
occupancy rate (Kapur et al., 1999). Although this equipotency of
both doses cannot be provided by our data, it should be noted that
PET and SPECT data are difficult to compare because of the broad
range of methodological differences between these techniques.
Generally, another confounding variable in those studies is the
difference in time interval between last medication intake and
SPECT scanning.
Our study is not without limitations. In our risperidone-treated
group, three patients were treated for only 1 week. However, the
percentage D2 occupancy did not differ from the mean value of the
whole group when only those patients with a minimum treatment
of 2 weeks were considered. Additionally, a clear correlation
between daily dose of risperidone and the degree of D2 receptor
binding compared to olanzapine was demonstrated. We could not
204 JOURNAL OF PSYCHOPHARMACOLOGY 16(3)
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collect plasma levels at the time of SPECT investigations, but the
relatively high D2 receptor occupancy made us confident that the
compliance of our inpatients was good. Furthermore, patients were
not randomly assigned in a prospective fashion to take fixed-
multiple dose regimes for clinically relevant doses of risperidone
and olanzapine. Additionally, we cannot provide standardized data
on clinical symptoms or EPS in our patient groups.
Problems of nuclear medicine imaging technique data from
SPECT or PET, with respect to comparing D2 receptor occupancy,
clinical efficacy and side-effects in different treatment regimes,
have only recently become apparent. From a methodological
viewpoint, the real benefit of novel antipsychotics in comparison to
each other and with respect to classical antipsychotics may be
obscured in drug trials with non-equipotent dosing (Nyberg and
Farde, 2000). A first remarkable PET study in this field was
performed in order to evaluate the minimal effective dose of
risperidone by fixed different and subsequently administered doses
in a sample of schizophrenic patients (Nyberg et al., 1999). By
investigating the relationship between dose, plasma concentration
and D2 and 5-HT2A receptor occupancy of risperidone, guidelines
for the minimal effective dosing of risperidone emerged. A relevant
receptor occupancy of 70–80% with risperidone given at a daily
dose of 4 mg with minimal risk of extrapyramidal side-effects was
detected.
Atypical neuroleptics have been characterized by a minimally
ten-fold higher affinity for 5-HT2A than for dopamine D2
receptors. In combination with a threshold level of striatal D2
receptor occupancy between 74% and 82%, this is regarded as the
main protection against the severe side-effects, especially
concerning EPS, of the classical neuroleptics (Meltzer et al., 1989;
Farde et al., 1992). Risperidone and olanzapine exhibit this 5-
HT2A versus D2 receptor blocking capability, at least in animal
experiments (Bymaster et al., 1996; Schotte et al., 1996). Despite
its clozapine-like structure, olanzapine equals risperidone
regarding an affinity for the cloned human D2 receptor (Bymaster
et al., 1996; Schotte et al., 1996). Clinical experience, on the other
hand, nevertheless shows different EPS-inducing behaviour of both
substances: patients treated with risperidone develop EPS more
often than those treated with olanzapine (Bymaster et al., 1996;
Tran et al., 1997a; Leucht et al., 1999; Remington and Kapur,
1999). Our data support the hypothesis that the clinically
documented difference between risperidone and olanzapine for the
incidence of EPS cannot be explained solely by blocking of the
striatal D2 receptor. Other components of the receptor binding
profiles of both substances (i.e. binding to the 5-HT-system or the
muscarinic receptors) may play an important role in this respect
(Bymaster et al., 1996; Schotte et al., 1996).
Fast dissociation from the dopamine D2 receptor caused by a
low affinity at the D2 receptor without reference to any other
receptor profile is sufficient to produce atypical antipsychotic
activity (Seeman and Tallerico, 1999; Kapur and Seeman 2001). It
was suggested that antipsychotic drugs with k-values > 2 nmol/l
(e.g. olanzapine and clozapine) elicit low levels of parkinsonism
because they bind more loosely than dopamine itself at the D2
receptor (Seeman and Tallerico, 1998, 1999). Finally, comparative
studies using different radioligands also need to reflect the
potential variable displacement of the antipsychotic drug due to
higher or lower affinity of the competing radioligand (Seeman and
Van Tol, 1995).
Recent data concerning another difference between risperidone
and olanzapine (i.e. the different capability to block NMDA-
antagonist-induced alterations of brain metabolism in the rat)
(Duncan et al., 2000) extend the field of discussion regarding this
topic and certainly have to be further evaluated in this context.
Olanzapine, but not risperidone, blocks ketamine-induced 2-DG
uptake in different brain regions of the rat (Duncan et al., 2000).
The same difference was shown by this group for clozapine versus
haloperidol. Further characteristics of risperidone and olanzapine
therefore seem to be important, which somehow make risperidone
more similar to haloperidol despite its more or less identical D2
blocking properties, even in vivo. Interestingly, a higher dose of
olanzapine was required to completely block the ketamine-effects
than would be expected if the D2 and 5-HT2 receptor blocking
properties of olanzapine were solely responsible for its action.
These data may support the importance of analysis of the schizo-
phrenic illness as a combined glutamatergic-dopaminergic, or
cortico-striato-thalamico-cortical feedback disorder (Weinberger,
1987).
In conclusion, using SPECT, we demonstrated in vivo the
degree of striatal dopamine D2 receptor binding in a large sample
of 20 patients with schizophrenia, who were being treated with
risperidone, and compared these data with the degree of striatal
dopamine D2 receptor binding of olanzapine. Our study
demonstrated an exponential dose–response relationship in 20
patients treated with 2–8 mg of risperidone daily. Comparison of
the risperidone-treated group with the olanzapine-treated group
revealed no significant difference with respect to striatal D2
receptor binding of IBZM or the D2 receptor occupancy rate
induced by the two substances. Our results indicate that the
dose–response relationship of risperidone is similar and closer to
that of haloperidol than to that of clozapine. Risperdone occupies a
considerable percentage of D2 receptors in vivo in a large range of
clinically relevant doses.
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